---
title: "Guangdong HEC Pharma says China regulator accepts HEC-921 cancer drug trial application"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290206381.md"
description: "Guangdong HEC Pharmaceutical announced that China's drug regulator has accepted the clinical trial application for HEC-921, a LY6G6D/4-1BB bispecific antibody injection. Phase I testing is scheduled to begin in 2026, targeting advanced solid tumors, with an initial focus on LY6G6D-positive colorectal cancer."
datetime: "2026-06-18T13:23:23.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290206381.md)
  - [en](https://longbridge.com/en/news/290206381.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290206381.md)
generator: "portal-rs"
---

# Guangdong HEC Pharma says China regulator accepts HEC-921 cancer drug trial application

-   Guangdong HEC Pharmaceutical’s China drug regulator accepted a clinical trial application for HEC-921, a LY6G6D/4-1BB bispecific antibody injection. \* Phase I testing is expected to start in 2026, targeting advanced solid tumors with an initial focus on LY6G6D-positive colorectal cancer. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guangdong HEC Pharmaceutical Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260618-12208904), on June 18, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [600673.CN](https://longbridge.com/en/quote/600673.CN.md)
- [00388.HK](https://longbridge.com/en/quote/00388.HK.md)
- [80388.HK](https://longbridge.com/en/quote/80388.HK.md)
- [HKXCY.US](https://longbridge.com/en/quote/HKXCY.US.md)

## Related News & Research

- [Faron Pharmaceuticals to host investor R&D Day on bexmarilimab program](https://longbridge.com/en/news/298544684.md)
- [Alpha-9 Oncology doses first patient in Phase 1 trial of GRPR-targeted radiotherapeutics](https://longbridge.com/en/news/298604842.md)
- [CordenPharma aumenta la capacità di riempimento e finitura asettici fino a 500 milioni di unità sterili iniettabili all'anno](https://longbridge.com/en/news/298671744.md)
- [Sarine affiliate KITOV.ai launches X-Prime automated surface inspection system](https://longbridge.com/en/news/298477765.md)
- [Vincere Biosciences Awarded $2.7 Million NIH Grant to Advance USP30 Inhibitor for Acute Kidney Injury](https://longbridge.com/en/news/298589159.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**